Clemson and Diversa to Collaborate on the Development of Enzymes to Enhance Human Nutrition

CLEMSON, S.C. and SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Clemson University and Diversa Corporation (Nasdaq: DVSA) today announced that they are collaborating to assess opportunities to leverage existing Diversa enzymes that have the potential to enhance human nutrition. The parties will initially focus on evaluating the ability of protein supplements to food to improve stamina and alertness and reduce fatigue.

Clemson scientists have ongoing programs to investigate diet and health, including the study of herbal remedies. Diversa is interested in improving the nutritional impact of food by using novel enzymes. Merging the benefits of diet with pharmaceuticals and modern genomic tools has created a rapidly growing global business area in nutrition. The Institute of Nutraceutical Research at Clemson is focused on deploying new technology to meet the needs of this new field. Diversa has developed a portfolio of commercialized enzyme products and an extensive pipeline of candidate enzymes and other proteins with industrial, chemical, agricultural, and pharmaceutical applications that have potential applications in diet and nutrition.

"Diversa's strengths in discovery and optimization of novel proteins are highly complementary with Clemson's research capabilities in nutrition, animal science, biochemistry, and chemical engineering," said David Gangemi, Ph.D., Director of Clemson's Institute of Nutraceutical Research. "Diversa's well- established capabilities allow our institute to rapidly test and develop new nutraceutical compounds and be more competitive in federal grant programs."

"Clemson University and The Institute of Nutraceutical Research have developed impressive capabilities to accelerate the practical deployment of new technology aimed at improving human nutrition," said Jay M. Short, Ph.D., Diversa's President and Chief Executive Officer. "The Institute's ability to organize and run clinical testing programs and their established packaging and formulation expertise will help bring novel protein solutions to the consumer in a rapid, effective, safe, and economical process. We are excited about working with Clemson on proteins we are currently developing as well as working together to improve the competitiveness of both of our federal grant programs to develop new technologies."

A key goal of Clemson's expanding biotechnology program is to enhance the economy of South Carolina by developing public-private research collaborations. SC Bio, under the direction of the Institute of Nutraceutical Research, supports development of private corporate research and funding relationships.

"Our emerging relationship with Diversa represents an important corporate research collaboration in the life science industry. We believe this type of alliance will be pivotal in advancing research and creating new commercial avenues for South Carolina technologies," said SC Bio CEO Karl Kelly, Ph.D.. "This is the result of South Carolina's continued efforts to attract and cultivate this industry to the state."

The mission of the Institute of Nutraceutical Research is to make Clemson University the national leader in nutritional research. Its goals are to help state industries develop greater confidence in product quality and effectiveness, enhance consumer demand for S.C. nutraceutical products, and develop economic opportunities for rural S.C. communities.

"Clemson continues to identify commercial opportunities that will expand the agriculture industry in South Carolina by supporting both new crop production and related processing opportunities," said John Kelly, Ph.D., Vice President for Public Service and Agriculture at Clemson University, "Clemson University will continue its mission to expand corporate relationships that benefit the state's economy."

About Diversa

Diversa, headquartered in San Diego, is a leader in the discovery and evolution of novel protein-based products using proprietary genomic technologies. Diversa is directing its integrated portfolio of technologies to the discovery, evolution, and production of commercially valuable molecules with agricultural, chemical, industrial, and pharmaceutical applications. Diversa has established alliances and joint ventures with market leaders, such as Bayer Animal Health, Cargill Health and Food Technologies, DuPont Bio-Based Materials, GlaxoSmithKline, Medarex, Merck, and Xoma. In addition, Diversa has formed a broad strategic relationship with Syngenta AG, a world-leading agribusiness company. Diversa has commercialized products both independently and in collaboration with strategic partners and licensees. Additional information is available at Diversa's website:

Forward-Looking Statements

Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty. These include statements related to the ability of Diversa and Clemson to realize any of the proposed benefits of their collaboration, including their ability to effectively deploy Diversa's technologies and enzymes to rapidly develop new nutraceutical compounds and otherwise enhance human nutrition, and the collaboration's ability to improve South Carolina's economy, all of which are prospective. Such statements are only predictions, and the actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to differences include, but are not limited to, risks involved with Diversa's new and uncertain technologies, Diversa's dependence on patents and proprietary rights, Diversa's protection and enforcement of its patents and proprietary rights, Diversa's dependence on collaborators for development and commercialization of products, including as part of its collaboration with Clemson, Diversa's and its collaborators' ability to commercialize products, the time and resources needed to develop new products and obtain any necessary regulatory approvals, customer adoption of new products, and the development or availability of competitive products or technologies. Certain of these factors and others are more fully described in Diversa's filings with the Securities and Exchange Commission, including, but not limited to, Diversa's Annual Report on Form 10- K for the year ended December 31, 2004. These forward-looking statements speak only as of the date hereof. Diversa expressly disclaims any intent or obligation to update these forward-looking statements.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.